Literature DB >> 11077440

Expression of Brca1 and splice variant Brca1delta11 RNA levels in mouse mammary gland during normal development and tumorigenesis.

M Mixon1, F Kittrell, D Medina.   

Abstract

Expression of Brca1 in mouse mammary cancer has yet to be analysed. We use a progressive model of neoplasia based on several mouse epithelial cell lines that represent distinct steps toward the fully tumorigenic state. Using RNase protection analysis because acceptable anti-Brca1 antibodies are not available we investigated the expression of Brca1 and a splice variant, Brca1Delta11, in several mammary hyperplasias and tumors that arose from them, and in normal mammary gland through pregnancy and involution. Expression of Brca1 was highest in rapidly proliferating cells. Expression of the full-length Brca1 was detectable in the virgin gland, was slightly elevated in the midpregnant gland, and decreased to levels similar to the age-matched virgin gland in the completely involuted gland. Expression of both forms of Brca1 was detectable in 9/9 paired hyperplasias and tumors, with levels of total Brca1, but not the splice variant Brca1Delta11, in tumors higher than those in the hyperplasias. While in disagreement with the observation that Brca1 levels decrease in human breast cancer progression, these patterns support the notion that Brca1 expression is associated with proliferating cells, and suggests that the link with differentiation seen in normal cells can be removed when cells become tumorigenic.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11077440     DOI: 10.1038/sj.onc.1203905

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

1.  Tumorigenesis in mice carrying a truncating Brca1 mutation.

Authors:  T Ludwig; P Fisher; S Ganesan; A Efstratiadis
Journal:  Genes Dev       Date:  2001-05-15       Impact factor: 11.361

Review 2.  Hormone-induced protection against breast cancer.

Authors:  Lakshmi Sivaraman; Daniel Medina
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-01       Impact factor: 2.673

Review 3.  Emerging roles of BRCA1 alternative splicing.

Authors:  T I Orban; E Olah
Journal:  Mol Pathol       Date:  2003-08

4.  BRCA1 is a novel regulator of metabolic function in skeletal muscle.

Authors:  Kathryn C Jackson; Eva-Karin Gidlund; Jessica Norrbom; Ana P Valencia; David M Thomson; Rosemary A Schuh; P Darrell Neufer; Espen E Spangenburg
Journal:  J Lipid Res       Date:  2014-02-24       Impact factor: 5.922

5.  The gene encoding the splicing factor SF2/ASF is a proto-oncogene.

Authors:  Rotem Karni; Elisa de Stanchina; Scott W Lowe; Rahul Sinha; David Mu; Adrian R Krainer
Journal:  Nat Struct Mol Biol       Date:  2007-02-18       Impact factor: 15.369

6.  Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer.

Authors:  Xiaoling Liu; Henne Holstege; Hanneke van der Gulden; Marcelle Treur-Mulder; John Zevenhoven; Arno Velds; Ron M Kerkhoven; Martin H van Vliet; Lodewyk F A Wessels; Johannes L Peterse; Anton Berns; Jos Jonkers
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-11       Impact factor: 11.205

7.  Evolutionary conservation analysis increases the colocalization of predicted exonic splicing enhancers in the BRCA1 gene with missense sequence changes and in-frame deletions, but not polymorphisms.

Authors:  Christopher Pettigrew; Nicola Wayte; Paul K Lovelock; Sean V Tavtigian; Georgia Chenevix-Trench; Amanda B Spurdle; Melissa A Brown
Journal:  Breast Cancer Res       Date:  2005-09-22       Impact factor: 6.466

Review 8.  Serine/arginine-rich splicing factors: the bridge linking alternative splicing and cancer.

Authors:  Xiang Zheng; Qiu Peng; Lujuan Wang; Xuemei Zhang; Lili Huang; Jia Wang; Zailong Qin
Journal:  Int J Biol Sci       Date:  2020-07-06       Impact factor: 6.580

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.